New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Thermo Fisher Scientific Inc.

TMO

Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.67%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

670.06 18.69 −2.71%

After hours trading: 673.50, up 0.51%, last trade Fri 6:42pm Eastern.

Market cap
$255.5B
P/E
35.3×
Fwd P/E FY26e
35.9×
Dividend yield
0.27%
F-score
5/9
ROIC
6.03%
Net debt / EBITDA
2.4×
Payout ratio
0.1×

Thermo Fisher Scientific Inc. (TMO) revenue by segment, product and region

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.